BRAF and neoplasm: Recently published SECOMBIT and DREAMseq trial data reported that first-line immunotherapy has a survival benefit, which may account for some of the differences seen in survival by BRAF status.24,25 In the period 2016–21 there was no adjuvant systemic anticancer therapy approved for stage I/II melanoma, so patients who received systemic anticancer therapy may have had BRAF testing of an archival primary tumour following relapse and should not be considered as having had stage I/II melanoma at the time of testing.